Compare CRSP & TKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | TKC |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | Switzerland | Turkey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.2B |
| IPO Year | 2016 | 2001 |
| Metric | CRSP | TKC |
|---|---|---|
| Price | $60.11 | $6.71 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $70.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 785.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.29% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,603.19 | $45.35 |
| Revenue Next Year | $78.75 | $30.18 |
| P/E Ratio | ★ N/A | $26.98 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $5.35 |
| 52 Week High | $78.48 | $7.60 |
| Indicator | CRSP | TKC |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 50.48 |
| Support Level | $58.40 | $5.48 |
| Resistance Level | $60.40 | $7.18 |
| Average True Range (ATR) | 3.03 | 0.11 |
| MACD | 1.16 | -0.05 |
| Stochastic Oscillator | 86.78 | 15.86 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.